Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46

Journal of Virology

Volumn 83, Issue 10, 2009, Pages 4844-4853

  Hermann, Felix G ^a   Egerer, Lisa ^a   Brauer, Frances ^a   Gerum, Christian ^b   Schwalbe, Harald ^b   Dietrich, Ursula ^a   Von Laer, Dorothee ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C PEPTIDE MAC46; CD4 ANTIGEN; CHEMOKINE RECEPTOR; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; VIRUS RNA;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL MEMBRANE; CONCENTRATION (PARAMETERS); CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PRIORITY JOURNAL; SYSTEM ANALYSIS; VIRUS ENVELOPE; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE; CELL LINE; GENETICS; METABOLISM;

GREAT ISLAND VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

C-PEPTIDE; CELL LINE; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS; RNA, VIRAL;

EID: 65349113010     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00666-08     Document Type: Article

References (41)

1. Abrahamyan, L. G., S. R. Mkrtchyan, J. Binley, M. Lu, G. B. Melikyan, and F. S. Cohen. 2005. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J. Virol. 79:106-115. (Pubitemid 39648368)
2. Baba, M., O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, Y. Iizawa, M. Shiraishi, Y. Aramaki, K. Okonogi, Y. Ogawa, K. Meguro, and M. Fujino. 1999. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96:5698-5703.
3. Baldwin, C. E., R. W. Sanders, Y. Deng, S. Jurriaans, J. M. Lange, M. Lu, and B. Berkhout. 2004. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78:12428-12437. (Pubitemid 39458761)
4. Bogan, A. A., and K. S. Thorn. 1998. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280:1-9. (Pubitemid 28312802)
5. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
6. Chinnadurai, R., D. Rajan, J. Munch, and F. Kirchhoff. 2007. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J. Virol. 81:6563-6572. (Pubitemid 46878060)
7. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367. (Pubitemid 30666686)
8. Dervillez, X., A. Huther, J. Schuhmacher, C. Griesinger, J. H. Cohen, D. von Laer, and U. Dietrich. 2006. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. Chem. Med. Chem. 1:330-339.
9. Desmezieres, E., N. Gupta, R. Vassell, Y. He, K. Peden, L. Sirota, Z. Yang, P. Wingfield, and C. D. Weiss. 2005. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120. J. Virol. 79:4774-4781.
10. Egelhofer, M., G. Brandenburg, H. Martinius, P. Schult-Dietrich, G. Melikyan, R. Kunert, C. Baum, I. Choi, A. Alexandrov, and D. von Laer. 2004. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol. 78:568-575. (Pubitemid 38067578)
11. Giroglou, T., J. Cinatl, Jr., H. Rabenau, C. Drosten, H. Schwalbe, H. W. Doerr, and D. von Laer. 2004. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J. Virol. 78:9007-9015. (Pubitemid 39096512)
12. Greenberg, M., N. Cammack, M. Salgo, and L. Smiley. 2004. HIV fusion and its inhibition in antiretroviral therapy. Rev. Med. Virol. 14:321-337. (Pubitemid 39222465)
13. Greenberg, M. L., and N. Cammack. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54:333-340.
14. Heil, M. L., J. M. Decker, J. N. Sfakianos, G. M. Shaw, E. Hunter, and C. A. Derdeyn. 2004. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J. Virol. 78:7582-7589. (Pubitemid 38915905)
15. Hermann, F. G., H. Martinius, M. Egelhofer, T. Giroglou, T. Tonn, S. D. Roth, R. Zahn, P. Schult-Dietrich, A. Alexandrov, U. Dietrich, C. Baum, and D. von Laer. 6 February 2009. Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides. Hum. Gene Ther. doi:1089/hum.2006.158.
16. Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-74.
17. Lee, B., M. Sharron, L. J. Montaner, D. Weissman, and R. W. Doms. 1999. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA 96:5215-5220.
18. Liu, S., W. Jing, B. Cheung, H. Lu, J. Sun, X. Yan, J. Niu, J. Farmar, S. Wu, and S. Jiang. 2007. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282:9612-9620.
19. Lohrengel, S., F. Hermann, I. Hagmann, H. Oberwinkler, L. Scrivano, C. Hoffmann, D. von Laer, and M. T. Dittmar. 2005. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J. Virol. 79:10237-10246. (Pubitemid 41098565)
20. McCammon, J. A. 1998. Theory of biomolecular recognition. Curr. Opin. Struct. Biol. 8:245-249. (Pubitemid 28221058)
21. Melby, T., R. Demasi, N. Cammack, G. D. Miralles, and M. L. Greenberg. 2007. Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249. AIDS Res. Hum. Retrovir. 23:1366-1373.
22. Melikyan, G. B., M. Egelhofer, and D. von Laer. 2006. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J. Virol. 80:3249-3258.
23. Melikyan, G. B., R. M. Markosyan, H. Hemmati, M. K. Delmedico, D. M. Lambert, and F. S. Cohen. 2000. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151:413-423.
24. Naldini, L., U. Blömer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
25. Nameki, D., E. Kodama, M. Ikeuchi, N. Mabuchi, A. Otaka, H. Tamamura, M. Ohno, N. Fujii, and M. Matsuoka. 2005. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J. Virol. 79:764-770. (Pubitemid 40053859)
26. Nevo, R., V. Brumfeld, R. Kapon, P. Hinterdorfer, and Z. Reich. 2005. Direct measurement of protein energy landscape roughness. EMBO Rep. 6:482. (Pubitemid 40767083)
27. Park, E. J., and G. V. Quinnan, Jr. 1999. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J. Virol. 73:5707-5713.
28. Platt, E. J., J. P. Durnin, and D. Kabat. 2005. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 79:4347-4356.
29. Platt, E. J., D. M. Shea, P. P. Rose, and D. Kabat. 2005. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J. Virol. 79:4357-4368.
30. Reeves, J. D., S. A. Gallo, N. Ahmad, J. L. Miamidian, P. E. Harvey, M. Sharron, S. Pohlmann, J. N. Sfakianos, C. A. Derdeyn, R. Blumenthal, E. Hunter, and R. W. Doms. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 99:16249-16254.
31. Reeves, J. D., J. L. Miamidian, M. J. Biscone, F. H. Lee, N. Ahmad, T. C. Pierson, and R. W. Doms. 2004. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J. Virol. 78:5476-5485.
32. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993. (Pubitemid 28116876)
33. Schambach, A., B. Schiedlmeier, K. Kuhlcke, M. Verstegen, G. P. Margison, Z. Li, K. Kamino, J. Bohne, A. Alexandrov, F. G. Hermann, D. von Laer, and C. Baum. 2006. Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. Gene Ther. 13:1037-1047. (Pubitemid 43905856)
34. Schneider, S. E., B. L. Bray, C. J. Mader, P. E. Friedrich, M. W. Anderson, T. S. Taylor, N. Boshernitzan, T. E. Niemi, B. C. Fulcher, S. R. Whight, J. M. White, R. J. Greene, L. E. Stoltenberg, and M. Lichty. 2005. Development of HIV fusion inhibitors. J. Pept. Sci. 11:744-753. (Pubitemid 41684261)
35. Sista, P. R., T. Melby, D. Davison, L. Jin, S. Mosier, M. Mink, E. L. Nelson, R. DeMasi, N. Cammack, M. P. Salgo, T. J. Matthews, and M. L. Greenberg. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18:1787-1794.
36. Steger, H. K., and M. J. Root. 2006. Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem. 281:25813-25821. (Pubitemid 44401969)
37. Sterjovski, J., M. J. Churchill, A. Ellett, L. R. Gray, M. J. Roche, R. L. Dunfee, D. F. Purcell, N. Saksena, B. Wang, S. Sonza, S. L. Wesselingh, I. Karlsson, E. M. Fenyo, D. Gabuzda, A. L. Cunningham, and P. R. Gorry. 2007. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4:89.
38. Su, C., T. Melby, R. DeMasi, P. Ravindran, and G. Heilek-Snyder. 2006. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J. Clin. Virol. 36:249-257. (Pubitemid 44066892)
39. Trivedi, V. D., S. F. Cheng, C. W. Wu, R. Karthikeyan, C. J. Chen, and D. K. Chang. 2003. The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng. 16:311-317.
40. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905. (Pubitemid 34535213)
41. Yee, J.-K., A. Miyanohara, P. LaPorte, K. Bouic, J. C. Burns, and T. Friedmann. 1994. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91:9564-9568.